Phase 1 at City of Hope
A study evaluating safety and immunogenicity in recurrent epithelial ovarian cancer.
Read the study recordInnocell™ / Personalized cellular immunotherapy
Personalized cancer immunotherapy. Built from the patient’s own tumor.
PhotonPharma is developing Innocell, an investigational cellular immunotherapy being evaluated in a Phase 1 study for recurrent epithelial ovarian cancer.
01 / 04
A tumor’s own signature.
A patient’s tumor cells carry many different antigens. Those surface signals are the starting point for Innocell.
Patient-derived tumor cell · Surface antigens in gold
Drag to explore the cell. Choose a stage to follow the process.
Conceptual cellular illustration
Conceptual illustration · Not to scale. Innocell is investigational.
In clinical development
Phase 1 study at City of Hope
Innocell for recurrent
epithelial ovarian cancer
The development record
Science with a path to clinical evaluation.
Explore the study, research and development milestones behind Innocell.
A translational foundation
Published work includes a canine cancer case study and research in Vox Sanguinis. These are distinct from human clinical results.
Explore publicationsU.S. patent 12,280,039
Cancer vaccine compositions and methods of use. Issued April 22, 2025.
View the patentTerumo Blood and Cell Technologies
An August 2021 announcement described an MOU to collaborate on Innocell development.
Read the announcementThe tumor supplies the targets.
Solid tumors are heterogeneous: their cells can carry different antigens. Innocell keeps the patient’s broad tumor-antigen repertoire, rather than selecting a small set of targets.
Conceptual illustration · Not to scale
Personalized at the source
The patient’s tumor supplies the antigens. The approach preserves their breadth through the inactivation process.
Prepared without cell expansion
One tissue preparation can yield multiple doses. A turnaround of less than seven days is anticipated at commercial scale.
Innocell is investigational. Safety and immunogenicity are being evaluated in a Phase 1 study. The illustration explains the proposed mechanism; it does not depict clinical results.
Research and publicationsClinical development
Starting with recurrent ovarian cancer.
Innocell, recurrent epithelial ovarian cancer
Phase 1, City of Hope
An FDA-cleared study evaluating safety and immunogenicity. ClinicalTrials.gov NCT06366490.
View clinical studyInnocell with bevacizumab, ovarian cancer
Phase 1b plannedA planned combination cohort in the ovarian cancer program.
Lung, colorectal, breast, melanoma
Preclinical developmentPotential expansion into additional solid tumors.
Canine cancer
Published case studyEarly translational work reported by Goodrich et al., J. Immunol. Res. (2020).
Development overview reviewed November 2026. The clinical registry was last updated March 27, 2026; planned and preclinical programs are not evidence of clinical efficacy. US patent 12,280,039 covers Innocell compositions. Innocell is an investigational therapy and is not approved for commercial use.
Investors & partners
Understand the platform. Follow the evidence.
A patient-derived approach, a defined lead indication and a team with experience across clinical development, manufacturing and regulatory affairs.
Explore PhotonPharmaBuilt by people who have taken therapies to market.
Ray Goodrich, PhD
Co-founder, CEO and CSO; Director
Co-founder of Innocell and former Chief Scientific Officer at Terumo BCT, with experience in transfusion medicine and pathogen reduction.
Read biography
Thomas Bogenrieder, MD, PhD
(Acting) Chief Medical Officer
More than 20 years in immuno-oncology clinical development, including leadership roles at Boehringer Ingelheim and GSK.
Read biography
Christopher J. Welsh
Director of Quality Assurance
Three decades across medical technology development, quality systems, manufacturing and regulatory compliance.
Read biography
Susan Yonemura, PhD
Director of Product Development
Bioengineering expertise across medical devices and biopharma, with a focus on Innocell product development.
Read biography
David Reinhold Brill, PhD
Director of Regulatory Affairs
More than 35 years of regulatory leadership, including drug development, approvals and commercialization at Boehringer Ingelheim.
Read biography
Beth Crump
Director of Clinical Affairs
Clinical development experience spanning preclinical through post-marketing programs and Phase I–III trials.
Read biographyNews and publications.
personalized-cancer-vaccines.com
prnewswire.com
prnewswire.com
singularityhub.com
coloradosun.com
prnewswire.com
Talk to us.
Connect with our team.
admin@photonpharma.netPhotonPharma, Inc., Research Innovation Center, 3185 Rampart Road, Fort Collins, CO 80523.
Research Innovation Center · Colorado State University
A note on recruitment scams
A note on recruitment scams. PhotonPharma has been made aware of employment scams misrepresenting our company. We do not use outside recruiters. Official correspondence comes only from @photonpharma.net addresses, and we would never request a payment or financial information during recruiting. To verify a contact, email admin@photonpharma.net. Report scams to the FTC at reportfraud.ftc.gov or the FBI at ic3.gov.